Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(55)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 NV7Td|BxS3m2b4TvfIlkKEG|c3H5 M1fvRlExKG6P NHqwUHg4OiCq MmHXSG1UVw>? NVPWTYg1WG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MlqzNlQ6ODB6N{O=
HT-29 MmjPR5l1d3SxeHnjJGF{e2G7 NWnM[ndtOTBibl2= NFPiSHI4OiCq NXrBbXloTE2VTx?= NHiz[mRRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= NUn4RZM6OjR7MEC4O|M>
HT-29 NYXKVGx[S3m2b4TvfIlkKEG|c3H5 MVGxNEBvVQ>? NX\iWWhTPzJiaB?= NGXudndFVVOR M2LucHBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NFz6TlczPDlyMEi3Ny=>
PC3 Ml7NT4lv[XOnIFHzd4F6 Mn\1NVAxKG6P NGrLRVgyKGh? M3PWWGROW09? M3Lvd3BwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u NHjkNFQzOTl5OE[4Ny=>
PC3 NHXrSZVMcW6jc3WgRZN{[Xl? MYWxNFAhdk1? M{HnVFEhcA>? MknNSG1UVw>? NUHRU4lETG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MkC5NlE6Pzh4OEO=
PC3 NIPETmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexMlUh|ryP M1:1PVEhcA>? NGDPWVlFVVOR NWXTTXM5UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N M3[zWFIyQTd6Nkiz
HEK293 MUXGeY5kfGmxbjDBd5NigQ>? Mn\hNVAxKG6P NI[zd285KGh? MXjEUXNQ NH72WFdKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NXzZVlFDOjF3M{mzNFE>
BT-20 MXvLbY5ie2ViQYPzZZk> M3rEcVIxKM7:TR?= MVvEUXNQ MVfEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? MYWyNVM2OzV3MR?=
U937 MYPBcpRq[mGldHXybYFtKEG|c3H5 M2O4UFUxKM7:TR?= NFrPemM1QCCq NYLGWnJkTE2VTx?= M3zWOWlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= MWmyNVE1OjFyNh?=
U937 MWfBcpRq[mGldHXybYFtKEG|c3H5 M2LTTlUxKM7:TR?= M3W4elQ5KGh? MnTnSG1UVw>? NWjUZnZ7TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NVHONWdPOjFzNEKxNFY>
U937 M2rCO2FvfGmkYXP0[ZJq[WxiQYPzZZk> MUm1NEDPxE1? NInIS2c1QCCq NEX6W45FVVOR M{\GSmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ M1vZdVIyOTR{MUC2
MCF-7 M1;WeGF2fG:yaHHnfUBCe3OjeR?= NVSwSXNNOzBibl2= MWW0JIg> NVX2SVZ2TE2VTx?= Mn7OTY5lfWOnczDheZRweGijZ4m= NWLsdVlXOjByMkixN|Q>
U87MG MkDlT4lv[XOnIFHzd4F6 Ml7oNUDPxE1? NWW2[5I6PiCq NXXPepNETE2VTx?= NXzhT25vWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= NFTONJkyQTh2OESwOC=>
U87MG Mn;tT4lv[XOnIFHzd4F6 MkLuNUDPxE1? M2HGd|YhcA>? NXrq[nA1TE2VTx?= NHHRc4FRd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=> MUexPVg1QDRyNB?=
U87MG Mm\HT4lv[XOnIFHzd4F6 MlmzNUDPxE1? MnuwOkBp Mn;tSG1UVw>? MWfEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MW[xPVg1QDRyNB?=
U87MG NIjrRlVMcW6jc3WgRZN{[Xl? NX;qdmdROSEQvF2= NVThenN7PiCq NF3ucVBFVVOR NFnUdXlFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? NHHXdpEyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb NGr6Wo9CfXSxcHjh[5khSXO|YYm= MV:wMlIh|ryP NGTxb48zPCCq M2m5UWROW09? NETKTJVKdmS3Y3XzJIF2fG:yaHHnfS=> NWXQNnZEOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NWf0d3hOSXW2b4DoZYd6KEG|c3H5 NVfo[WRZOC5{IN88US=> NHHVeXMzPCCq NWrOZpo4TE2VTx?= MUDJcoR2[2W|IHH1eI9xcGGpeR?= MmHuNVg{QTF7NEm=
H4 NUnJNWd4TnWwY4Tpc44hSXO|YYm= Ml3RNE4zKM7:TR?= MYmyOEBp MVXEUXNQ MknWTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> M1jpXFE5ODJ2NUi0
HeLa NVq1VZRPTnWwY4Tpc44hSXO|YYm= M{LwT|ExOCCwTR?= Ml3JN|YhcA>? MYnEUXNQ MlyyTY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=> MlXsNVc2PjN|OEW=
HeLa MoXWSpVv[3Srb36gRZN{[Xl? MlHlNVAxKG6P NFTrOZU{PiCq NULDeGI3TE2VTx?= NHLST5RKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? MYixO|U3OzN6NR?=
HeLa M3\rPGZ2dmO2aX;uJGF{e2G7 MmHJNVAxKG6P M1HvXVM3KGh? NHnjfnZFVVOR NInLOFNKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NWft[JY5OTd3NkOzPFU>
SYF NHvwTItHfW6ldHnvckBCe3OjeR?= NHPlUYwyODBibl2= M{\NNlI1KGh? M4\pS2ROW09? NXTQW2pmUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MWCxO|U3OzN6NR?=
SYF NUnjU2xST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNFAhdk1? Ml;yNlQhcA>? M320RmROW09? NFzJOWtKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz M1ftRVE4PTZ|M{i1
HEK293T NFq0e2JCdnSrdnnyZYwhSXO|YYm= NXy4NpV3OSCwTR?= MlrKOEBl NFf1VoRFVVOR NYPifnY4UW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> NUPTZYVEOTd2OEW1NFE>
HEK293T NYPhXncySW62aY\pdoFtKEG|c3H5 NHXxSYIyKG6P MmHEOEBl MWHEUXNQ MmDTTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= M37te|E4PDh3NUCx
PBMC MWPGeY5kfGmxbjDBd5NigQ>? M1O2eFEhdk1? M3nieFE1KGR? MXHEUXNQ M1n1ZnJm\HWlZYOgR2NTPSCmZX7zbZR6 NHHnd|MyPzR6NUWwNS=>
PBMC MXfGeY5kfGmxbjDBd5NigQ>? NGHwbpUyKG6P NIjRNnEyPCCm MV3EUXNQ MkT0SI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> Mn3wNVc1QDV3MEG=
HEK293 cells MXrLbY5ie2ViQYPzZZk> NUnUdJlzPTBibl2= MmDEOFUhdWmw MWjEUXNQ M1[5[GlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? M4HxRVE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MVLGeY5kfGmxbjDBd5NigQ>? MonDNVAxKG6P NGjwSo41KGh? M1nGdWROW09? NUXEeGZPUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NYTMZ4xMOTdzMkiyOlI>
Human mixed lymphocyte MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nuelUhdk1? M3fFfGROW09? MUjJR|UxRTFwNjDuUU4> MlXPNVYyQDV6NkW=
Lewis rat lymph node cells NFvVfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrMeIw2PSEQvF2= M{DGbGROW09? NVLnfHZwUUN3ME2yMlYh|ryP MW[xOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice M2PidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHGNXMyOCCwTR?= M3TuSVczKGh? MkTSSG1UVw>? NIL2RmpKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N NYTwc4NSOTByMkG5OFg>
MRK-nu-1 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K2fWlEPTB;MD64OFUheE1? NXjzbGpGW0GQR1XS
OCUB-M M3ns[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPES2M1UUN3ME21MlI1KHCP MXTTRW5ITVJ?
SF539 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFzLk[gdG0> M2HDOXNCVkeHUh?=
ES4 NXn1fVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETrR5ZKSzVyPUKxMlUheE1? M1;RR3NCVkeHUh?=
RL95-2 NYHMUXJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFyNzDwUS=> M{DjPHNCVkeHUh?=
LC-2-ad MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTCTWM2OD12MkOgdG0> M2HWXHNCVkeHUh?=
Daudi NUDpRYEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR|NDDwUS=> NGPkdJRUSU6JRWK=
NTERA-S-cl-D1 NGjwSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDRRnNOUUN3ME20OFMheE1? M4jLUHNCVkeHUh?=
OS-RC-2 NXnUcndXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGxV4dKSzVyPU[1NkBxVQ>? M1u1ZnNCVkeHUh?=
VA-ES-BJ MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3sTWM2OD15MkOgdG0> Mlz6V2FPT0WU
GR-ST MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTh2NjDwUS=> MoDXV2FPT0WU
SW872 NWrFPFdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf0T3hyUUN3ME24OFYheE1? MV;TRW5ITVJ?
NOS-1 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XtdWlEPTB;OEexJJBO M4G4UXNCVkeHUh?=
MC116 NEnIdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLG[3NsUUN3ME25PFUheE1? NH\MRnlUSU6JRWK=
NCI-H1355 NF\pdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P5RWlEPTB;MT6wNUBvVQ>? MkTLV2FPT0WU
RPMI-8226 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7FTWM2OD1zLkG5JI5O MmrEV2FPT0WU
TE-15 M4\ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFwM{[gcm0> NFnkXG5USU6JRWK=
Ramos-2G6-4C10 NGG4Z25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTTTWM2OD1zLkS2JI5O NVXRRphjW0GQR1XS
KU812 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwMEGgcm0> M3rTNXNCVkeHUh?=
EW-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTFTWM2OD1{LkG3JI5O MmTQV2FPT0WU
KS-1 M1XsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHZW3dSUUN3ME2yMlQ2KG6P M{nr[nNCVkeHUh?=
SK-LMS-1 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y0cmlEPTB;Mj60PUBvVQ>? NWHTVm5yW0GQR1XS
TGBC1TKB NEDNS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXtOldKSzVyPUKuOlkhdk1? NIr3NlNUSU6JRWK=
TE-6 M4eyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ONXRKSzVyPUKuO|chdk1? M2rk[HNCVkeHUh?=
ETK-1 M1TBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLRTWM2OD1{LkiyJI5O NYnjTIx1W0GQR1XS
BE-13 M{PIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG0fIdKSzVyPUKuPVkhdk1? Ml3KV2FPT0WU
A3-KAW MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fkT2lEPTB;Mj65PUBvVQ>? NVLsVZdCW0GQR1XS
TE-10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL4e5F1UUN3ME2zMlMhdk1? Mle0V2FPT0WU
DOHH-2 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HMXmlEPTB;Mz6zOUBvVQ>? MljqV2FPT0WU
ES6 NW[2XFluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P2XmlEPTB;Mz60N{BvVQ>? NIDtOZJUSU6JRWK=
OPM-2 NGfTe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XuTmlEPTB;ND6xOUBvVQ>? NYHVTXdiW0GQR1XS
SH-4 M1PYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTRwM{Sgcm0> M4rZWnNCVkeHUh?=
NB13 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DLdmlEPTB;ND6zOkBvVQ>? NYDNe4V{W0GQR1XS
HUTU-80 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T0fGlEPTB;ND60NkBvVQ>? MorpV2FPT0WU
CCRF-CEM MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPVTWM2OD12Lkm0JI5O MWjTRW5ITVJ?
TGBC24TKB M3yyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHwco1jUUN3ME21MlUyKG6P NY\oR3RrW0GQR1XS
697 M4\xXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn1eGF3UUN3ME22MlI5KG6P MUPTRW5ITVJ?
J-RT3-T3-5 M3\lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGwVXhwUUN3ME22MlQ3KG6P NV7aSI15W0GQR1XS
KALS-1 NXKyZm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n1bWlEPTB;Nj61OkBvVQ>? MVfTRW5ITVJ?
no-10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLRTWM2OD15LkK5JI5O MmDtV2FPT0WU
SK-NEP-1 M{ixU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PWcWlEPTB;OD63PUBvVQ>? NInjRY5USU6JRWK=
L-540 M3nIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln4TWM2OD1zMD60NkBvVQ>? NFHNcVFUSU6JRWK=
JiyoyeP-2003 M{XE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFyLkm0JI5O NF\B[HdUSU6JRWK=
HH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULRbWxNUUN3ME2xNU4{QSCwTR?= NEDqfpZUSU6JRWK=
SR M3Lke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFzLkS1JI5O M2m3OHNCVkeHUh?=
QIMR-WIL NXPkWpA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFzLki1JI5O MXPTRW5ITVJ?
A4-Fuk MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF|LkGyJI5O NI\ZT3hUSU6JRWK=
CESS NF34RZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\5TWM2OD1zMz6xN{BvVQ>? M2HOc3NCVkeHUh?=
KE-37 M1zhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrIb5V[UUN3ME2xOk4xPyCwTR?= NXnse45LW0GQR1XS
SK-UT-1 NF34[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnhTWM2OD1zNj64NUBvVQ>? MmTkV2FPT0WU
SIG-M5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3IVGpWUUN3ME2xO{4zPSCwTR?= M17tZXNCVkeHUh?=
HT M2DqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF5Lk[gcm0> NET0d5RUSU6JRWK=
DEL MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnToTWM2OD1zNz65PUBvVQ>? NHHaZXpUSU6JRWK=
SK-PN-DW NEXFTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nkXWlEPTB;MkCuNlMhdk1? NG\zPXNUSU6JRWK=
RPMI-8402 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\4VmlEPTB;MkGuO|chdk1? M{\OUXNCVkeHUh?=
RPMI-6666 M4rZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TnbGlEPTB;MkSuOFIhdk1? M{LL[3NCVkeHUh?=
NCI-H720 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDRTWM2OD1{NT60NUBvVQ>? M3mzU3NCVkeHUh?=
EW-16 NELhZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;sTHU2UUN3ME2yOk45PyCwTR?= MkTxV2FPT0WU
BL-70 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ6LkO4JI5O MX7TRW5ITVJ?
SF126 NF\2ZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzFTWM2OD1|MD6zPEBvVQ>? NILSZ2xUSU6JRWK=
BC-1 MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\DdGlEPTB;M{GuNlYhdk1? MVPTRW5ITVJ?
MHH-PREB-1 NIfmWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrOTWM2OD1|Mj60OEBvVQ>? M4i4[nNCVkeHUh?=
A101D NIfHdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN{Lk[yJI5O M2jkWnNCVkeHUh?=
NMC-G1 NIe0fnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPBVWxKSzVyPUOzMlY4KG6P MUTTRW5ITVJ?
LB1047-RCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTN2Lk[5JI5O MVzTRW5ITVJ?
EM-2 MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nYOmlEPTB;M{iuOVMhdk1? NFH2c3FUSU6JRWK=
COLO-684 NXnSdnhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3MTWM2OD1|OT64JI5O NWX5RoMxW0GQR1XS
Becker NV3jeppzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvib5RKSzVyPUSxMlA2KG6P NH;ZTFRUSU6JRWK=
BL-41 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTR|Lk[2JI5O MY\TRW5ITVJ?
MDA-MB-134-VI NGf1UZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;XTWM2OD12ND6wNkBvVQ>? MWTTRW5ITVJ?
L-363 NETkT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzYZ4ZGUUN3ME20OE44OyCwTR?= NX;3bHppW0GQR1XS
ECC4 NI\OU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\2fWlEPTB;NESuO|ghdk1? MknHV2FPT0WU
A388 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zPW2lEPTB;NESuPFIhdk1? NWHEOYJlW0GQR1XS
HEL NYXDPWxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP1[HVKSzVyPUS5Mlc6KG6P M1X2eXNCVkeHUh?=
RKO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHP[4lKSzVyPUWwMlI6KG6P NGLRcYVUSU6JRWK=
KINGS-1 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVzLkW1JI5O NF;HSo1USU6JRWK=
EB-3 Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInNXVJKSzVyPUWyMlY4KG6P M3vnPXNCVkeHUh?=
ARH-77 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTV{Lkigcm0> NGrUOGJUSU6JRWK=
GCIY NVuxO3E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTV|LkS2JI5O M3HxRXNCVkeHUh?=
NCI-H1304 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTV5LkKyJI5O NV;NfGtZW0GQR1XS
KARPAS-299 NGewdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTZzLkiyJI5O NF;yXoxUSU6JRWK=
IA-LM M{K2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHtemVyUUN3ME22PE4yOyCwTR?= MXLTRW5ITVJ?
GI-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHflZlVKSzVyPUewMlM6KG6P MVvTRW5ITVJ?
TE-11 M2PxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTd5LkG3JI5O NH\STWtUSU6JRWK=
LS-411N MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTDUYdpUUN3ME23O{42PyCwTR?= MWPTRW5ITVJ?
no-11 NIXZZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTFSldKSzVyPUizMlI1KG6P MYHTRW5ITVJ?
MV-4-11 M{H2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\PPWlEPTB;OEOuO|Mhdk1? MmH3V2FPT0WU
BV-173 M2KxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzUTWM2OD16Mz65O{BvVQ>? MoH2V2FPT0WU
CMK NF;v[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTh2LkG2JI5O NGq3e5hUSU6JRWK=
LC4-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzuTWM2OD16Nj63NkBvVQ>? MVLTRW5ITVJ?
COR-L279 NYraUXR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ftb2lEPTB;OEeuNlUhdk1? M1u5SXNCVkeHUh?=
NCI-H209 MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLyTWM2OD16Nz60NUBvVQ>? NIrhU5JUSU6JRWK=
Raji M2[5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LseWlEPTB;OEmuO|Ihdk1? MUDTRW5ITVJ?
LB996-RCC NGT0VGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTl|LkSzJI5O MkjlV2FPT0WU
NCI-H526 NHG5bWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLDTWM2OD17Mz61PUBvVQ>? NWj1[G5UW0GQR1XS
KGN MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPTbmxKSzVyPUm2MlI6KG6P NXm1O4NGW0GQR1XS
MOLT-4 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PXOGlEPTB;OU[uO|khdk1? NF:2Vo1USU6JRWK=
PF-382 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jTN2lEPTB;OU[uO|khdk1? NWL1WW1kW0GQR1XS
BC-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPqTWM2OD17OT6xPEBvVQ>? NH;QOXhUSU6JRWK=
KARPAS-422 NGfUcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i2R2lEPTB;MUCyMlA6KG6P MmrCV2FPT0WU
SBC-1 NYqzWVFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Jcm9KSzVyPUGwO{44PSCwTR?= NFnR[FZUSU6JRWK=
LC-1F NVvqTGtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHCTWM2OD1zMEiuNFUhdk1? NYjmbmxsW0GQR1XS
GB-1 NUHXTG0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[2Z2lEPTB;MUC5MlAzKG6P NVi4UphCW0GQR1XS
SNB75 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe4fplKSzVyPUGxPU43QSCwTR?= M3L2cHNCVkeHUh?=
BB65-RCC M3fRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnuTo44UUN3ME2xNVkvQTNibl2= MX\TRW5ITVJ?
NCI-N87 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHBTWM2OD1zMkGuPVghdk1? NED2cW1USU6JRWK=
IST-MEL1 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrGN3BKSzVyPUGyNk4{QCCwTR?= NXjTbI5zW0GQR1XS
HOP-62 NU\pUoEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPwUVlKSzVyPUGyOk45QSCwTR?= NXnPXopFW0GQR1XS
ACN M4LN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF2Nj63OUBvVQ>? NULhfpJOW0GQR1XS
DMS-114 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzLTWM2OD1zNUCuOlchdk1? MVTTRW5ITVJ?
MLMA NWfmN2FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL6SlZKSzVyPUG1PU45QCCwTR?= NYO0SZdHW0GQR1XS
HT-144 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLPb|dKSzVyPUG2OU41OyCwTR?= NH7x[XZUSU6JRWK=
C2BBe1 M3zpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPjN2lKSzVyPUG2O{44PiCwTR?= NU\aZVNHW0GQR1XS
L-428 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq2NIRKSzVyPUG3O{44KG6P MW\TRW5ITVJ?
DU-4475 NFXpWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULoT3NXUUN3ME2xPFcvPjhibl2= M4jKXXNCVkeHUh?=
CP67-MEL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF7OT6zPEBvVQ>? NXvyc3hZW0GQR1XS
MEG-01 M4nCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjwdmhkUUN3ME2yNFEvQTZibl2= NIO4[2JUSU6JRWK=
IST-SL2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJyOD62N{BvVQ>? NVvXc2tFW0GQR1XS
ES8 NF\Gco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K1fWlEPTB;MkK1Mlk1KG6P MlToV2FPT0WU
COLO-800 M3rYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHrO2JUUUN3ME2yN|UvOjhibl2= NH\TfoFUSU6JRWK=
MFH-ino MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmflTWM2OD1{M{WuPFQhdk1? MmGyV2FPT0WU
OVCAR-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPWSIxPUUN3ME2yN|cvOjRibl2= M1HoWnNCVkeHUh?=
PSN1 M32wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTJbohKSzVyPUK0Nk44OSCwTR?= MlP2V2FPT0WU
EW-12 MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn6TWM2OD1{NEOuNUBvVQ>? M3K1Z3NCVkeHUh?=
HCC1599 NYTl[Zo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vIcmlEPTB;Mk[xMlQ4KG6P NX;vNYJqW0GQR1XS
SJSA-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi1dJVTUUN3ME2yO|EvPDZibl2= M37CeHNCVkeHUh?=
ST486 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ7Nj6xOEBvVQ>? NVzWXopOW0GQR1XS
NOMO-1 NEP6VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\WUXJKSzVyPUOwNE4zOSCwTR?= NVn0Nm5ZW0GQR1XS
MN-60 NYG2TJV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnmxTWM2OD1|MEWuN|Ihdk1? MlSwV2FPT0WU
HCC1187 NHHZ[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLuTWM2OD1|MEeuNlUhdk1? M4f4N3NCVkeHUh?=
SW982 NVHHSHhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DzWmlEPTB;M{G0Mlc2KG6P Ml[wV2FPT0WU
LB647-SCLC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTN{OD63NUBvVQ>? Mn;VV2FPT0WU
HC-1 M3zCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN|NT61JI5O M1q0U3NCVkeHUh?=
EHEB NFXlN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrNTWM2OD1|M{euOVIhdk1? MXfTRW5ITVJ?
TUR NX65VpRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHPNoZvUUN3ME2zOlMvQTVibl2= MkL1V2FPT0WU
LU-139 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvkSXJbUUN3ME2zO|gvODJibl2= NVHwU4hFW0GQR1XS
NB1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjDTWM2OD1|OESuOFUhdk1? MlK1V2FPT0WU
BB30-HNC MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fTWGlEPTB;M{i4MlMzKG6P NFrGOldUSU6JRWK=
HAL-01 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHqWFFKSzVyPUO4PU4zPiCwTR?= NYey[oY1W0GQR1XS
K5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRzMT6zO{BvVQ>? MVXTRW5ITVJ?
MZ2-MEL M4Wxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXQ[HpGUUN3ME20NVMvPjRibl2= Mn;VV2FPT0WU
RXF393 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmyOlZKSzVyPUSxOk41PSCwTR?= NUS1SYdXW0GQR1XS
NCI-H1648 NWnzNZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ezWGlEPTB;NEG3MlU{KG6P NXn1UoF1W0GQR1XS
TE-12 Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zmUGlEPTB;NEO0MlI3KG6P M2q4c3NCVkeHUh?=
EoL-1- MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe4VGptUUN3ME20N|cvQThibl2= NHTDeXFUSU6JRWK=
JAR NICwPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfRWFNKSzVyPUSzPE43OiCwTR?= NFHocZFUSU6JRWK=
DSH1 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR3OD65NUBvVQ>? NH33SWRUSU6JRWK=
NCI-H187 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLUVVRKSzVyPUS2Nk45OSCwTR?= Mn23V2FPT0WU
HCE-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfOTWM2OD12N{euOlYhdk1? NIDodHRUSU6JRWK=
8-MG-BA NGC0ZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD5TWM2OD13OEGuOVIhdk1? NE\VPXJUSU6JRWK=
KLE NFKydFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjOT25KSzVyPUW4OU4zKG6P M3XXOnNCVkeHUh?=
KNS-42 Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH2cHNKSzVyPUW4Ok45OSCwTR?= MoLHV2FPT0WU
MSTO-211H MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7NbJZKSzVyPU[wPU44PCCwTR?= MlPkV2FPT0WU
GDM-1 NV7MNnF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PETmlEPTB;NkG0MlA6KG6P MX;TRW5ITVJ?
TE-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTZ2Nj6xNkBvVQ>? MWrTRW5ITVJ?
BT-474 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUmxUmRxUUN3ME22OFcvODZibl2= NUDnSppDW0GQR1XS
KARPAS-45 NYjtN|l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1exXmlEPTB;NkS3MlYhdk1? MoHkV2FPT0WU
MOLT-16 M3jMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDqW3RIUUN3ME22OFcvQTNibl2= NVPuRmZlW0GQR1XS
KURAMOCHI M4fRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTZ3Nz61NUBvVQ>? MkHSV2FPT0WU
K-562 NGDTOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jVRWlEPTB;Nk[5MlUyKG6P MknQV2FPT0WU
EKVX MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3qTWM2OD14N{KuO|Ehdk1? NH;pRVBUSU6JRWK=
GAK NUjhcZFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTZ5NT6zJI5O MV\TRW5ITVJ?
NCI-SNU-5 NUjRWHh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzRR5BKSzVyPU[5NE4xOSCwTR?= M2\vOHNCVkeHUh?=
NCI-H2126 NHXjUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTd{Nj64O{BvVQ>? MX;TRW5ITVJ?
CTV-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOzTWM2OD15NESuPUBvVQ>? MVrTRW5ITVJ?
SW962 NI\4codIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XRO2lEPTB;N{S4MlQ1KG6P Mn76V2FPT0WU
MONO-MAC-6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHUTWM2OD15NU[uPVMhdk1? NYPER|AzW0GQR1XS
NCI-H748 NWPrW4FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q4U2lEPTB;N{W4Mlk6KG6P Mlq1V2FPT0WU
NCI-H524 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq1bGFKSzVyPUe4NE44OyCwTR?= M{j1VXNCVkeHUh?=
LS-123 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTd7NT62PUBvVQ>? MnHVV2FPT0WU
NB7 NFLWPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRThzND6xOEBvVQ>? NW\nVG0yW0GQR1XS
LS-1034 NYnVU4NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrLXJVKSzVyPUiyPE46QCCwTR?= NYDMUIp2W0GQR1XS
TE-5 NEHsXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PQcGlEPTB;OEizMlU3KG6P MUnTRW5ITVJ?
A704 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn63TWM2OD16OUmuNVUhdk1? MVHTRW5ITVJ?
TK10 M3y3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PmOGlEPTB;OUG2MlA{KG6P MlrpV2FPT0WU
NCI-H345 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme3TWM2OD17NEOuNlIhdk1? M{TsOnNCVkeHUh?=
CGTH-W-1 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjTTWM2OD17NEiuNVMhdk1? NHfaVHFUSU6JRWK=
NCI-H510A MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe2SlBKSzVyPUm4OU4yOiCwTR?= NVvGWXRFW0GQR1XS
NCI-H1963 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwMEOyPVIh|ryP M3z5bHNCVkeHUh?=
SCC-3 NFmzVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KybGlEPTB;MT6wN|QyPCEQvF2= MV;TRW5ITVJ?
EW-11 M1rKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwMEi3OFMh|ryP M3rO[3NCVkeHUh?=
CPC-N M33EdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DlRWlEPTB;MT6wPFgh|ryP M{jOPHNCVkeHUh?=
NCI-H1417 NI\TdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TuR2lEPTB;MT6xNlI3KM7:TR?= MnP5V2FPT0WU
DG-75 NYPJcnVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTZTWM2OD1zLkG2Nlg2KM7:TR?= MmTEV2FPT0WU
HD-MY-Z MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf5dmRKSzVyPUGuNVY1OTZizszN MUDTRW5ITVJ?
ATN-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvMUpNbUUN3ME2xMlI3OjB7IN88US=> MkjUV2FPT0WU
KM-H2 M1fad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf1ZoNKSzVyPUGuNlY1ODhizszN M1Tad3NCVkeHUh?=
NCI-H2081 M2DCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfwbYdyUUN3ME2xMlI3PjN5IN88US=> MmSxV2FPT0WU
HL-60 M1fnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDNNFlKSzVyPUGuNlY6PTlizszN MUXTRW5ITVJ?
DB NHHIXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwMkeyOFIh|ryP NXrj[ItIW0GQR1XS
NCI-H1522 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPVTWM2OD1zLkK4PFg4KM7:TR?= NXXRTJdrW0GQR1XS
AM-38 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFwM{C3NkDPxE1? MUDTRW5ITVJ?
NCI-H446 M4rDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn5TWM2OD1zLkOyNVIyKM7:TR?= NYOydIhuW0GQR1XS
SU-DHL-1 NVyyXphTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDPXlRZUUN3ME2xMlMzQDBzIN88US=> MUnTRW5ITVJ?
NH-12 NVTZcWNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwM{[zO|Qh|ryP MoXiV2FPT0WU
DMS-79 NHrZOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXWe3VtUUN3ME2xMlM3QDZ4IN88US=> MV7TRW5ITVJ?
NCI-H716 M1nK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDCSpdKSzVyPUGuN|g6QDZizszN M2jzN3NCVkeHUh?=
ML-2 NVqwPIxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVyxeW43UUN3ME2xMlQyPTJ7IN88US=> MXrTRW5ITVJ?
NB10 NIXUOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DXV2lEPTB;MT60OlY{OiEQvF2= MoLqV2FPT0WU
ONS-76 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwNUO1Olkh|ryP NEjiV|VUSU6JRWK=
LOUCY NITPVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOzTWM2OD1zLkW0OlU4KM7:TR?= M3XsfnNCVkeHUh?=
SCLC-21H NX7mUJE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHHVINKSzVyPUGuOVg2QDJizszN NXH3UGtMW0GQR1XS
TGW NILaOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrFZYdKSzVyPUGuOlM6PzVizszN MXvTRW5ITVJ?
LXF-289 NFvpcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDvTWM2OD1zLkezNlY5KM7:TR?= M1\y[3NCVkeHUh?=
BB49-HNC NEXvSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvxUXFKSzVyPUGuO|M2QDZizszN NV\WdWY2W0GQR1XS
NCI-H747 NUTKXWJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PpXGlEPTB;MT63OVM1PiEQvF2= MUXTRW5ITVJ?
LU-165 NVfuWJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwOES5PFYh|ryP NVLxeVFrW0GQR1XS
OMC-1 MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTnTWM2OD1zLkm1NFY3KM7:TR?= MoC1V2FPT0WU
RCC10RGB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHHTWM2OD1zLkm1PFE4KM7:TR?= MmLKV2FPT0WU
SW684 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmniTWM2OD1zLkm2NFk6KM7:TR?= MV\TRW5ITVJ?
TE-8 NWnR[Yk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTiTWM2OD1{LkC1OVU6KM7:TR?= NUjnboxKW0GQR1XS
SK-N-DZ NYnkNmJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jxWWlEPTB;Mj6xN|I4PCEQvF2= NUH4bm42W0GQR1XS
EVSA-T M3T4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDUN2VKSzVyPUKuNVc{OTVizszN MXPTRW5ITVJ?
KASUMI-1 M1[xUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC0RZpKSzVyPUKuNVg5OTVizszN Ml7NV2FPT0WU
NKM-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwMkW0O|Ih|ryP MnvMV2FPT0WU
CAL-148 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{eyfmlEPTB;Mj6zN|YyPCEQvF2= M32yTHNCVkeHUh?=
NCI-H64 NVyxdZFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rq[2lEPTB;Mj6zOFI{OiEQvF2= MVfTRW5ITVJ?
KNS-81-FD MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJwM{[2NkDPxE1? NEjJc2tUSU6JRWK=
KM12 M2\SVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7BfmlCUUN3ME2yMlQxQDN7IN88US=> M{LaPHNCVkeHUh?=
SW954 NGTPO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\kOJFKSzVyPUKuOFc4PzlizszN MUjTRW5ITVJ?
NCI-H1395 NHjG[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmwOnpKSzVyPUKuOVI3PDVizszN NUn1VYhDW0GQR1XS
DJM-1 M2HGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3sTWM2OD1{Lk[wOlMh|ryP MW\TRW5ITVJ?
COLO-668 MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHrSFdKSzVyPUKuPFI3QTVizszN NEjINGhUSU6JRWK=
NCI-H1436 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF74cXhKSzVyPUKuPFU3OTVizszN NEHaV5dUSU6JRWK=
LB2241-RCC M3;u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJwOE[4N|kh|ryP NXjVN4FUW0GQR1XS
GT3TKB NXXkUmpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;oRnpKSzVyPUKuPFkxPTVizszN NYDaV21rW0GQR1XS
COLO-824 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7ITWM2OD1{Lki5O|Y5KM7:TR?= NGrtcFJUSU6JRWK=
ES1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC2c5hKSzVyPUKuPFk5PzlizszN NWPhOFhSW0GQR1XS
LB771-HNC NVTjSm9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfEUZhOUUN3ME2yMlkxQTR4IN88US=> NHvVXXZUSU6JRWK=
GI-ME-N NHSxZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TxOGlEPTB;Mz6wNFkxPCEQvF2= NVjhN|Z7W0GQR1XS
NALM-6 NIfrSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwMEC5N|Mh|ryP MoP3V2FPT0WU
LU-134-A MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KzPGlEPTB;Mz6wOVQzPSEQvF2= NVjPdGZKW0GQR1XS
DMS-153 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH2SmI{UUN3ME2zMlA2QDJ2IN88US=> M4GzTHNCVkeHUh?=
MZ1-PC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\1[3N1UUN3ME2zMlA6ODd6IN88US=> M1yxSHNCVkeHUh?=
NCI-H1155 NXH1O5l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG2[JRFUUN3ME2zMlEyPjFizszN MnzqV2FPT0WU
CAS-1 Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7CVIdEUUN3ME2zMlE{PzB5IN88US=> MXPTRW5ITVJ?
D-502MG NVfSOJI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf4e5FKSzVyPUOuNVQ{QSEQvF2= MofiV2FPT0WU
NCI-H2141 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO4[ZV[UUN3ME2zMlE4PDV{IN88US=> NXz0V2JGW0GQR1XS
NB6 M4HveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGwTWM2OD1|LkG4NlU6KM7:TR?= MX\TRW5ITVJ?
NCCIT NHPkUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT5N4pKUUN3ME2zMlIyQDB7IN88US=> NIHkfG1USU6JRWK=
NB69 M4nPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTZXnlHUUN3ME2zMlMyQDlzIN88US=> M{fBeHNCVkeHUh?=
JVM-2 M{PpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHZUFlKUUN3ME2zMlM3PDN|IN88US=> MVrTRW5ITVJ?
K052 M2m1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LCbWlEPTB;Mz6zO|k3QCEQvF2= M{nPNXNCVkeHUh?=
HCC2157 M{LRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XXOGlEPTB;Mz61N|IzQCEQvF2= M2PMVXNCVkeHUh?=
KMOE-2 M{H6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTNwNUSyOFIh|ryP Ml7pV2FPT0WU
SF268 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljKTWM2OD1|LkexOVU1KM7:TR?= M3XxSXNCVkeHUh?=
CHP-126 NF3xboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[4ZWlEPTB;Mz63OlQ2QCEQvF2= M4XCO3NCVkeHUh?=
CP66-MEL Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPNcllQUUN3ME2zMlc6ODl2IN88US=> MXjTRW5ITVJ?
NCI-H69 NETKXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTRwMEG5N|Yh|ryP MnjQV2FPT0WU
A253 NW\YTmY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTWVHd6UUN3ME20MlAzOTBzIN88US=> MY\TRW5ITVJ?
NB14 M1ewcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrSTWM2OD12LkGwOFc6KM7:TR?= NFLtNGRUSU6JRWK=
NCI-H1694 M3:yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zDbmlEPTB;ND6xN|EyOiEQvF2= M{PaV3NCVkeHUh?=
NCI-H2196 NYfKSpI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{npbWlEPTB;ND6xO|E3QSEQvF2= MVrTRW5ITVJ?
TE-9 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwMUe1PFIh|ryP NEDxco5USU6JRWK=
D-283MED NYnrN2NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT4NlRKSzVyPUSuNVg5PCEQvF2= NH7JZ2hUSU6JRWK=
OCI-AML2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHM[WpKSzVyPUSuNVk1QDlizszN MXzTRW5ITVJ?
D-263MG M1rNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTRwMkK5OlEh|ryP MULTRW5ITVJ?
MPP-89 NWHmUFNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwMkezNFQh|ryP MlG5V2FPT0WU
LAMA-84 NELsSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1frT2lEPTB;ND6zNFQzOSEQvF2= MnTwV2FPT0WU
LB373-MEL-D M3X1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvKcXhKSzVyPUSuN|Y4QDlizszN NXraeZlxW0GQR1XS
UACC-257 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTRwM{m1N|Qh|ryP M{nyZXNCVkeHUh?=
MC-CAR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjHSYdKSzVyPUSuOFM6QSEQvF2= MoHMV2FPT0WU
COLO-320-HSR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTRwNES0Nlch|ryP MXnTRW5ITVJ?
P30-OHK NF3kdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorQTWM2OD12Lk[2OVgyKM7:TR?= NInIXIRUSU6JRWK=
UACC-812 NGDQTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq2TWM2OD12Lk[5NVYyKM7:TR?= MoHSV2FPT0WU
CTB-1 M4HRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPzV|VSUUN3ME20MlcyPTV3IN88US=> MmTSV2FPT0WU
ALL-PO MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnhb4xKSzVyPUSuPFQxPzdizszN MWXTRW5ITVJ?
SK-MEL-2 NUHvVYNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLrVmY4UUN3ME20Mlg3QTV3IN88US=> NGfuOGhUSU6JRWK=
TC-YIK MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33RSWlEPTB;ND65O|k1OiEQvF2= NHTm[45USU6JRWK=
NCI-H1882 NVPDcHo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC4XlJQUUN3ME21MlAzODBzIN88US=> Mn3tV2FPT0WU
MHH-CALL-2 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDXdmdKSzVyPUWuNFUxPDJizszN NHWyOXlUSU6JRWK=
U-87-MG NEfMc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD1TWM2OD13LkC5OFY3KM7:TR?= NU\i[XM{W0GQR1XS
NCI-H1092 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLUTWM2OD13LkK2OVU2KM7:TR?= MYXTRW5ITVJ?
TE-441-T M3zlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVntTYhQUUN3ME21MlI4QDJizszN MVjTRW5ITVJ?
SK-MEL-1 NIjwW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTZVG46UUN3ME21MlI6ODR2IN88US=> MlfBV2FPT0WU
EW-22 NYDVNHQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi2b5JKUUN3ME21MlI6PDZ4IN88US=> NVyyZZBwW0GQR1XS
MZ7-mel NWqwZoVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nmOGlEPTB;NT60NFY6OSEQvF2= NYj4S44{W0GQR1XS
LP-1 NHTKeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTVwNEGyPVEh|ryP NXLwcmgzW0GQR1XS
NCI-SNU-16 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLXc2NQUUN3ME21MlY1ODd2IN88US=> NVXzSohYW0GQR1XS
LU-65 NYTaXoVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonvTWM2OD13Lke2N|c{KM7:TR?= NX7rZ|dHW0GQR1XS
CW-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTVwOEW5OVkh|ryP MVXTRW5ITVJ?
WSU-NHL NEGycW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHYdWhmUUN3ME21Mlk2OTd2IN88US=> MVvTRW5ITVJ?
IST-MES1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTVwOUW0OFMh|ryP NFX0cGpUSU6JRWK=
U-266 NWGyVGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTVwOUiyNFIh|ryP NVTmZnJ2W0GQR1XS
TALL-1 NVfGeHhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofaTWM2OD14LkG0Olg5KM7:TR?= M1rmVXNCVkeHUh?=
Calu-6 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\SfJF4UUN3ME22MlE2OzF4IN88US=> M2LrRXNCVkeHUh?=
MMAC-SF NX7hd3lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmzepR4UUN3ME22MlE5PTV4IN88US=> NFPiPGpUSU6JRWK=
NCI-H82 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHD[3o2UUN3ME22MlIxPDh7IN88US=> NHPiUmtUSU6JRWK=
RS4-11 M13qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZwMkW4PVch|ryP MYjTRW5ITVJ?
SNU-C2B M4m2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO0fm5SUUN3ME22MlQxQTZ7IN88US=> NGnHPJlUSU6JRWK=
BOKU MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\DNGhKSzVyPU[uOFc2QTdizszN Mlf2V2FPT0WU
C8166 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnmTWM2OD14LkW1PVEzKM7:TR?= MYDTRW5ITVJ?
D-247MG NEfWco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj2VW5KSzVyPUeuNFQ{PDdizszN NGiwXJhUSU6JRWK=
EW-18 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\YbFZKSzVyPUeuNFczQTJizszN NGL2WGNUSU6JRWK=
KG-1 NIfS[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHzTWM2OD15Lk[yO|M5KM7:TR?= NV3NdXgzW0GQR1XS
REH M{foPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrMcIliUUN3ME23MlY5OTB7IN88US=> MYnTRW5ITVJ?
U-698-M NFvKVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojITWM2OD15Lki0N|E2KM7:TR?= MXHTRW5ITVJ?
KP-N-RT-BM-1 M4DkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2THfWlEPTB;Nz65N|AzQSEQvF2= NEjofo1USU6JRWK=
MS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nI[2lEPTB;Nz65OlA1OSEQvF2= M4XTV3NCVkeHUh?=
SNU-C1 NUjKe5pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj4[pRYUUN3ME23Mlk5OTl{IN88US=> MX;TRW5ITVJ?
SK-MM-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPsdYZKSzVyPUiuNlYxPjVizszN NYD6S3RqW0GQR1XS
LAN-6 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfEcnVKSzVyPUiuN|AxODFizszN NYnVdlVsW0GQR1XS
NEC8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XNTWlEPTB;OD6zNFY6OSEQvF2= MYrTRW5ITVJ?
NCI-H1770 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Lx[GlEPTB;OD6zPFAxOiEQvF2= Mnf0V2FPT0WU
D-336MG M1LyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7NTWM2OD16LkSwNVE3KM7:TR?= MVvTRW5ITVJ?
COLO-829 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jNXWlEPTB;OD60PFg4QSEQvF2= MWLTRW5ITVJ?
LS-513 M1HIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnlZ2pKSzVyPUiuOVk2QTlizszN NHjhRYdUSU6JRWK=
YT MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVntZXduUUN3ME24MlYzPDJ5IN88US=> MWHTRW5ITVJ?
EW-24 M2\JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDyTZFTUUN3ME24Mlc3PTRizszN MoTEV2FPT0WU
IST-SL1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jQXWlEPTB;OD64OlU1OyEQvF2= Ml\rV2FPT0WU
CA46 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XJc2lEPTB;OD65OVA6QCEQvF2= MYrTRW5ITVJ?
NCI-H1838 NEPEbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRThwOUi2NFIh|ryP M4f5T3NCVkeHUh?=
NCI-H719 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvMToxKSzVyPUmuNlUzPzlizszN M{G1SHNCVkeHUh?=
HCE-T M4rGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[zWmVKSzVyPUmuN|A5PTFizszN NUniXpJDW0GQR1XS
A498 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTlwM{[xNlQh|ryP M2\yTHNCVkeHUh?=
LB831-BLC M3HxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTlwN{[1NlEh|ryP MWjTRW5ITVJ?
SKM-1 NYfOPXFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTlwOEW5OlMh|ryP MoKzV2FPT0WU
THP-1 M2nXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG0XnRKSzVyPUmuPVY6OThizszN M3K3SHNCVkeHUh?=
SHP-77 NXjzeXdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\wUJRKSzVyPUGwMlQxPyEQvF2= MUfTRW5ITVJ?
EW-3 NXXyTnhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nrZmlEPTB;MUCuOlI5QSEQvF2= Mnu0V2FPT0WU
KY821 NHv2PG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q3R2lEPTB;MUCuO|Y{KM7:TR?= NHTqbGVUSU6JRWK=
NCI-SNU-1 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXoU|dJUUN3ME2xNU4xOjF5IN88US=> M1izcXNCVkeHUh?=
HCC2218 NYj4b2lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrJdJd7UUN3ME2xNU4{QTh4IN88US=> MWrTRW5ITVJ?
IM-9 NYGxb2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDUN4dKSzVyPUGxMlUyODZizszN M4n5dXNCVkeHUh?=
NCI-H889 NXH0WZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDnTWM2OD1zMT61N|E{KM7:TR?= NHHPWodUSU6JRWK=
HDLM-2 NV:0d2t6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF{LkSxOVkh|ryP MV;TRW5ITVJ?
LB2518-MEL M2LqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rKcWlEPTB;MUKuOlgyPSEQvF2= MWTTRW5ITVJ?
NCI-H23 NGPacJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16xO2lEPTB;MUOuNlQzPSEQvF2= Mn6wV2FPT0WU
NB17 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF|LkS1O|kh|ryP MmTKV2FPT0WU
NCI-H322M MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X6VWlEPTB;MUSuOFA3QCEQvF2= NFrIfm9USU6JRWK=
SUP-T1 Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrUNYFKSzVyPUG0MlQyOyEQvF2= M17zRnNCVkeHUh?=
ES3 NILifHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF3LkC3NFMh|ryP MX7TRW5ITVJ?
ES5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLSXm5KSzVyPUG1MlA4QDdizszN M1S2d3NCVkeHUh?=
NCI-H1650 M4jKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHkeVNKSzVyPUG1MlQ6PzlizszN NGrLZlJUSU6JRWK=
NCI-H226 NWDveJQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF3Lki3Olgh|ryP MoD2V2FPT0WU
COR-L88 M{LINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF4LkOxOEDPxE1? M1rFXHNCVkeHUh?=
SCC-15 M3PudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF4LkO4Olkh|ryP MXPTRW5ITVJ?
GOTO NI[xPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fMWmlEPTB;MU[uOFc6OyEQvF2= M{PtfXNCVkeHUh?=
SIMA NUXVblRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\3bGdOUUN3ME2xOk41QDB{IN88US=> NYfQbW5yW0GQR1XS
NCI-H1299 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnriTWM2OD1zNz6xOVkyKM7:TR?= NEjFOlRUSU6JRWK=
NCI-H1581 NI[zW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXzVFZKSzVyPUG3MlQzOTlizszN NWTmZ4pOW0GQR1XS
MHH-NB-11 M{Hmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2myPWlEPTB;MUeuPVY5OyEQvF2= NE[1NmZUSU6JRWK=
MFM-223 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF6LkC1N|gh|ryP M2OxbnNCVkeHUh?=
ES7 NFf1WYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnIb5ZKSzVyPUG4MlU1OzFizszN NGn5UW1USU6JRWK=
JVM-3 NXjyTHpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF6LkexO{DPxE1? MWPTRW5ITVJ?
RL Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnoTWM2OD1{MD6zPFgh|ryP MoXzV2FPT0WU
EC-GI-10 NVTFR4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P1ZWlEPTB;MkGuNlA1OSEQvF2= MVjTRW5ITVJ?
LNCaP-Clone-FGC NX[xeFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXRPXNKSzVyPUKxMlY4PjhizszN MX3TRW5ITVJ?
IMR-5 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\1TWM2OD1{MT64OFk1KM7:TR?= NWX2dno6W0GQR1XS
KP-N-YS NIT0PYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLaTWM2OD1{MT64O|Uh|ryP MV\TRW5ITVJ?
Mo-T NW\VVZpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn1bGt6UUN3ME2yNk4zOTh3IN88US=> NIK0WG9USU6JRWK=
NCI-H128 NGXFPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ|LkW4OVMh|ryP MV\TRW5ITVJ?
RH-1 NVXQWlE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ZV5ZKSzVyPUKzMlc5PjZizszN MWXTRW5ITVJ?
NCI-H2171 NIflPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;ITWM2OD1{ND6yOFg2KM7:TR?= M2XwcHNCVkeHUh?=
RPMI-8866 M1\FRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ4Lke0NkDPxE1? MWrTRW5ITVJ?
SK-N-FI NF\YfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fSe2lEPTB;MkeuN|gyOSEQvF2= MUDTRW5ITVJ?
LOXIMVI NVS2S5YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrBTWM2OD1{Nz64NFUyKM7:TR?= NIrpOplUSU6JRWK=
P31-FUJ M3PkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz4XFZKSzVyPUOxMlU{PzRizszN MXLTRW5ITVJ?
KMS-12-PE M4DnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW1eGp3UUN3ME20PU42OzB{IN88US=> MUXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーフィードバック (12)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy, 2015, 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep, 2015, 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol, 2015, 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

文献中の引用 (55)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ